Heron Therapeutics reports Q4 EPS (2c) vs 2c last year

Reports Q4 revenue $40.588M, consensus $39.53M. “As demonstrated in today’s release, we are entering 2026 with exceptional momentum. The fourth quarter delivered the strongest results in the history of Heron’s Acute Care franchise, underscoring the success of the strategic decisions we implemented to unlock the full potential of these assets,” said Craig Collard, Chief Executive Officer of Heron. “The milestones achieved in 2025, particularly for ZYNRELEF – including enhanced distributor-partner incentives, the seamless completion of the Vial Access Needle transition, and CMS approval of a product-specific J-Code – are already accelerating adoption and strengthening our competitive position in a large and underpenetrated market.”